Alumis shares jump 95% after envudeucitinib meets all endpoints in two phase III plaque psoriasis studies, showing strong skin clearance.

Amgen today announced its acquisition of Dark Blue Therapeutics Ltd., a privately held biotechnology company based in the United Kingdom advancing first-in-class, small molecule-targeted protein ...

Mapi is actively seeking new partnerships for its new proprietary Depot products. Company management will be available for one-on-one meetings during the J.P. Morgan Healthcare Conference to discuss ...